244 related articles for article (PubMed ID: 24498222)
1. p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress.
Ward A; Hudson JW
PLoS One; 2014; 9(1):e87918. PubMed ID: 24498222
[TBL] [Abstract][Full Text] [Related]
2. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice.
Ward A; Morettin A; Shum D; Hudson JW
BMC Cancer; 2011 Feb; 11():71. PubMed ID: 21324136
[TBL] [Abstract][Full Text] [Related]
4. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
[TBL] [Abstract][Full Text] [Related]
5. Gene expression patterns in heterozygous Plk4 murine embryonic fibroblasts.
Morettin A; Ward A; Nantais J; Hudson JW
BMC Genomics; 2009 Jul; 10():319. PubMed ID: 19607708
[TBL] [Abstract][Full Text] [Related]
6. The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.
Ward A; Sivakumar G; Kanjeekal S; Hamm C; Labute BC; Shum D; Hudson JW
Leuk Lymphoma; 2015 Jul; 56(7):2123-33. PubMed ID: 25347426
[TBL] [Abstract][Full Text] [Related]
7. SmSak, the second Polo-like kinase of the helminth parasite Schistosoma mansoni: conserved and unexpected roles in meiosis.
Long T; Vanderstraete M; Cailliau K; Morel M; Lescuyer A; Gouignard N; Grevelding CG; Browaeys E; Dissous C
PLoS One; 2012; 7(6):e40045. PubMed ID: 22768216
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-10B* is correlated with altered expression of mitotic kinases in osteosarcoma.
Roberto GM; Engel EE; Scrideli CA; Tone LG; Brassesco MS
Pathol Res Pract; 2018 Feb; 214(2):213-216. PubMed ID: 29254787
[TBL] [Abstract][Full Text] [Related]
9. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
[TBL] [Abstract][Full Text] [Related]
10. Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile.
Deng S; Lu X; Zhang Z; Meng R; Li M; Xia S
J Cell Mol Med; 2021 Jul; 25(14):6652-6663. PubMed ID: 34080290
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
[TBL] [Abstract][Full Text] [Related]
12. Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.
Kressin M; Fietz D; Becker S; Strebhardt K
Cells; 2021 May; 10(5):. PubMed ID: 34065956
[TBL] [Abstract][Full Text] [Related]
13. p53-dependent repression of polo-like kinase-1 (PLK1).
McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
[TBL] [Abstract][Full Text] [Related]
14. The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.
Iyer RS; Nicol SM; Quinlan PR; Thompson AM; Meek DW; Fuller-Pace FV
Cell Cycle; 2014; 13(9):1413-23. PubMed ID: 24626184
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1: target and regulator of transcriptional control.
Martin BT; Strebhardt K
Cell Cycle; 2006 Dec; 5(24):2881-5. PubMed ID: 17172872
[TBL] [Abstract][Full Text] [Related]
16. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
17. Functions of Polo-Like Kinases: A Journey From Yeast To Humans.
Vaid R; Sharma N; Chauhan S; Deshta A; Dev K; Sourirajan A
Protein Pept Lett; 2016; 23(2):185-97. PubMed ID: 26786872
[TBL] [Abstract][Full Text] [Related]
18. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
[TBL] [Abstract][Full Text] [Related]
19. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
